Products
Pre-Made Insulin Efsitora Alfa Biosimilar, Fusion Protein targeting INSR fused with human IGHG2 Fc (Fragment constant): Recombinant therapeutic protein targeting CD220/HHF5 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-870
Pre-Made Insulin Efsitora Alfa Biosimilar, Fusion Protein targeting INSR fused with human IGHG2 Fc (Fragment constant): Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Insulin Efsitora Alfa is a human insulin B-chain fused via a G2SG4 peptide linker to human insulin A-chain variant and a peptide linker to a human immunoglobulin G2 Fc fragment. It is used as an antidiabetic drug.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-870-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-870-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-870-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-870-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Insulin Efsitora Alfa Biosimilar, Fusion Protein targeting INSR fused with human IGHG2 Fc (Fragment constant): Recombinant therapeutic protein targeting CD220/HHF5 |
| INN Name | Insulin Efsitora Alfa |
| Target | INSR |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - INS (insulin, IDDM1, IDDM2, "insulin- dependent diabetes mellitus 2") - IGHG2 Fc (Fragment constant) |
| VD LC | Fusion - INS (insulin, IDDM1, IDDM2, "insulin- dependent diabetes mellitus 2") - IGHG2 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Eli Lilly (Indianapolis IN USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Facebook
LinkedIn
Twitter
